The oral delivery of proteins using interpolymer polyelectrolyte complexes

Therapeutic Delivery

Volumn 2, Issue 12, 2011, Pages 1611-1631

  Thompson, Colin ^a   Ibie, Chidinma ^a  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CHITOSAN; INSULIN; POLYASPARTIC ACID; POLYELECTROLYTE; POLYMETHACRYLIC ACID;

CELL MEMBRANE PERMEABILITY; COMPLEX FORMATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; MOLECULAR INTERACTION; NONHUMAN; PEYER PATCH; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN TRANSPORT; REVIEW; TIGHT JUNCTION;

EID: 81255207848     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.131     Document Type: Review

References (117)

1. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 19(3), 165-177 (2005). (Pubitemid 40994232)
2. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan -a review. J. Control. Release 114, 1-14 (2006). (Pubitemid 44131680)
3. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11(19-20), 905-910 (2006). (Pubitemid 44403178)
4. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22(4), 223-237 (2008). (Pubitemid 351969830)
5. Peppas NA, Carr DA. Impact of absorption and transport on intelligent therapeutics and nanoscale delivery of protein therapeutic agents. Chem. Eng. Sci. 64, 4553-4565 (2009).
6. Park K, Kwan IC, Park K. Oral protein delivery: current status and future prospect. React. Funct. Polym. 71, 280-287 (2011)
7. Singh R, Singh S, Lillard JW. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci. 97(7), 2497-2523 (2008).
8. Woodley F. Enzymatic barriers for Gl peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11, 61-95 (1994).
9. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20(2-3), 153-214 (2003). (Pubitemid 37237279)
10. Peppas NA, Kavimandan NJ. Nanoscale analysis of protein and peptide absorption: Insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur. J. Pharm. Sci. 29, 183-197 (2006). (Pubitemid 44602406)
11. Liu H, Wang Y, Li S. Advanced delivery of ciclosporin A: Present state and perspective. Expert Opin. Drug Deliv. 4, 349-358 (2007). (Pubitemid 47249136)
12. van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff J, Riis A, Noørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur. Urol. 52(1), 221-229 (2007). (Pubitemid 46803012)
13. Sajeesh S, Sharma CP. Novel polyelectrolyte complexes based on poly(methacrylic acid)-bis(2-aminopropyl)poly(ethylene glycol) for oral protein delivery. J. Biomater. Sci. Polym. Ed. 18, 1125-1139 (2007). (Pubitemid 47556678)
14. Lee Y-H, Sinko PJ. Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 42(3), 225-238 (2000). (Pubitemid 30645779)
15. Kidron M, Dinh S, Menachem Y et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet. Med. 21, 354-357 (2004). (Pubitemid 38519671)
16. Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJD. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277, 91-97 (2004). (Pubitemid 38670424)
17. Clement S, Dandona R, Still JG, Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53(1), 54-58 (2004). (Pubitemid 38071936)
18. des Rieux A, Ragnarsson EG, Gullberg E, Préat V, Schneider YJ, Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25(4-5), 455-465 (2005). (Pubitemid 40853873)
19. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial -Type 1. Diabetes Care 28(5), 1068-1076 (2005). (Pubitemid 40616615)
20. Cilek A, Celebi N, Tirnaksiz F. Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv. 13, 19-24 (2006). (Pubitemid 43087616)
21. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm. 325, 147-154 (2006). (Pubitemid 44573692)
22. Sarmento B, Ferreira D, Jorgensen L, van de Weert M. Probing insulin's secondary structure after entrapment into alginate-chitosan nanoparticles. Eur. J. Pharm. Biopharm. 65, 10-17 (2007). (Pubitemid 44827699)
23. Bayat A, Larijani B, Ahmadian S, Junginger HE, Rafiee-Tehrani M. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives. Nanomed. Nanotechnol. Biol. Med. 4, 115-120 (2008).
24. Woitiski CB, Veiga F, Ribeiro AJ, Neufeld RJ. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur. J. Pharm. Biopharm. 73, 25-33 (2009).
25. Woitiski CB, Neufeld RJ, Veiga F, Carvalho RA, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci. 41, 556-563 (2010).
26. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm. 412, 123-131 (2011).
27. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target. 12(2), 65-70 (2004). (Pubitemid 38786914)
28. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50, 3-12 (2000). (Pubitemid 30326685)
29. Bastian SE, Walton PE, Ballard FJ, Belford DA. Transport of IGF-I across epithelial cell monolayers. J. Endocrinol. 162, 361-369 (1999). (Pubitemid 29447429)
30. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld RJ, Ferreira D. Alginate-chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24(12), 2198-2206 (2007). (Pubitemid 350060707)
31. Agarwal V, Khan MA. Current status of the oral delivery of insulin. Pharm. Technol. 10, 76-90 (2001).
32. Guggi D, Kast CE, Bernkop-Schnürch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm. Res. 20(12), 1989-1994 (2003). (Pubitemid 38005530)
33. Desai MA, Mutlu M, Vadgama P. A study of macromolecular diffusion through native porcine mucus. Experientia 48, 22-26 (1992).
34. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34(2-3), 135-154 (1998). (Pubitemid 28535109)
35. Washington N, Washington C, Wilson CG. Physiological Pharmaceutics. Barriers to Drug Absorption (2nd Edition). Washington N, Washington C, Wilson CG (Eds). Taylor and Francis, London, UK (2002).
36. Serra L, Domenech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur. J. Pharm. Biopharm. 71(3), 519-528 (2009).
37. Bhalodia R, Basu B, Garala K, Joshi B, Mehta K. Buccoadhesive drug delivery systems: a review. Int. J. Pharm. Biosci. 1(2), 1-32 (2010).
38. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit. Rev. Biochem. Mol. Biol. 27, 57-92 (1992).
39. Liu Z, Wang S, Hu M. Chapter 11: Oral absorption basics: pathways, physico-chemical and biological factors affecting absorption. In: Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Qiu Y, Chen Y, Liu L, Zhang GGZ (Eds). Academic Press, London, UK (2009).
40. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58(1), 15-28 (2006).
41. Fix AJ. Oral controlled release technology for peptides: status and future prospects. Pharm. Res. 13, 1760-1764 (1996).
42. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46, 89-102 (2001).
43. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50(1), 147-160 (2000). (Pubitemid 30326694)
44. Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30(29), 5691-5700 (2009).
45. van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 22(7), 687-694 (2001). (Pubitemid 32112293)
46. Marks DL, Gores GJ, LaRusso NF. Hepatic processing of peptides. In: Peptide-Based Drug Design: Controlling Transport and Metabolism. Taylor MD, Amidon GL. (Eds). American Chemical Society, Washington, DC, USA (1995).
47. Swaan PW. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm. Res. 15, 826-834 (1998). (Pubitemid 28307822)
48. Schilling RJ, Mitra AK. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm. Res. 8(6), 721-727 (1991).
49. Zhou XH. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Release 29, 239-252 (1994).
50. Calceti P, Salmaso S, Walker G, Bernkop-Schnurch A. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22, 315-323 (2004). (Pubitemid 38758019)
51. Aoki Y, Morishita M, Asai K, Akikusa B, Hosoda S, Takayama K. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 22(11), 1854-1862 (2005). (Pubitemid 41504338)
52. Thompson CJ, Tetley L, Uchegbu IF, Cheng WP. The complexation between novel comb shaped amphiphilic polyallylamine and insulin -towards oral insulin delivery. Int. J. Pharm. 376, 46-55 (2009).
53. Thompson CJ, Tetley L, Cheng WP. The influence of polymer architecture on the protective effect of novel comb shaped amphiphilic poly(allyl amine) against in vitro enzymatic degradation of insulin -towards oral insulin delivery. Int. J. Pharm. 383, 216-227 (2010).
54. Yamamoto A, Taniguchi T, Rikyuu K et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11(10), 1496-1500 (1994). (Pubitemid 24339662)
55. Narayani R, Rao KP. Hypoglycemic effect of gelatin microspheres with entrapped insulin and protease inhibitor in normal and diabetic rats. Drug Deliv. 2(1), 29-38 (1995).
56. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int. J. Pharm. 111(3), 213-216 (1994). (Pubitemid 24292898)
57. Eaimtrakarn S, Rama Prasad YV, Ohno T et al. Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. J. Drug Target. 10(3), 255-260 (2002). (Pubitemid 34467295)
58. Hodges G, Carr EA, Hazzard RA, Carr KE. Uptake and translocation of microparticles in small intestine. Digest. Dis. Sci. 40(5), 967-975 (1995).
59. Spangler RS. Insulin administration via liposomes. Diabetes Care 13(9), 911-922 (1990). (Pubitemid 20260733)
60. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116(1), 1-27 (2006). (Pubitemid 44792295)
61. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J. Control. Release 13(2-3), 233-239 (1990). (Pubitemid 20313521)
62. Damgé C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86(12), 1403-1409 (1997).
63. Dünnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnürch A. Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int. J. Pharm. 408(1-2), 191-199 (2011).
64. Hartig SM, Greene RR, DasGupta J et al. Multifunctional nanoparticulate polyelectrolyte complexes. Pharm. Res. 24(12), 2353-2369 (2007). (Pubitemid 350060722)
65. Sajeesh S, Bouchemal K, Sharma CP, Vauthier C. Surface-functionalized polymethacrylic acid based hydrogel microparticles for oral drug delivery. Eur. J. Pharm. Biopharm. 74, 209-218 (2010).
66. Sajeesh S, Bouchemal K, Sharma CP, Vauthier C. Thiol-functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomaterialia 6, 3072-3080 (2010).
67. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 53(3), 321-339 (2001). (Pubitemid 34024913)
68. Ramkissoon-Ganorkar C, Liu F, Baudys M, Kim SW. Modulating insulin-release profile from pH/thermosensitive polymeric beads through polymer molecular weight. J. Control. Release 59(3), 287-298 (1999). (Pubitemid 29238173)
69. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release 86(2-3), 235-242 (2003). (Pubitemid 36084273)
70. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122(2), 141-150 (2007). (Pubitemid 47361403)
71. Wood KM, Stone G, Peppas NA. Wheat germ agglutinin functionalized complexation hydrogels for oral insulin delivery. Biomacromolecules 9, 1293-1298 (2008). (Pubitemid 351639584)
72. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20 (2001). (Pubitemid 32144788)
73. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114, 242-250 (2006). (Pubitemid 44291843)
74. Fan YF, Wang YN, Fan YG, Ma JB. Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption. Int. J. Pharm. 324, 158-167 (2006). (Pubitemid 44528909)
75. Simon M, Behrens I, Dailey LA, Wittmar M, Kissel T. Nanosized insulin-complexes based on biodegradable amine-modified graft polyesters poly[(vinyl-3-(diethylamino)-propylcarbamate-co-(vinyl acetate)-co-(vinyl alcohol)]-graft-poly(l-lactic acid): protection against enzymatic degradation, interaction with Caco-2 cell monolayers, peptide transport and cytotoxicity. Eur. J. Pharm. Biopharm. 66(2), 165-172 (2007). (Pubitemid 46654770)
76. Thompson CJ, Ding C, Qu X et al. The effect of polymer architecture on the nano self-assemblies based on novel comb-shaped amphiphilic poly(allylamine). Colloid Polym. Sci. 286, 1511-1526 (2008).
77. Cheng WP, Thompson CJ, Ryan SM, Aguirre T, Tetley L, Brayden DJ. In vitro and in vivo characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes. J. Control. Release 147, 289-297 (2010).
78. Thompson CJ, Cheng WP. Chemically modified polyelectrolytes for intestinal protein and peptide delivery. In: Peptide and Protein Delivery. Chris van der Walle (Ed.). Academic Press/Elsevier, San Diego, CA, USA (2011).
79. Thompson CJ, Cheng WP, Gadad P et al. Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells -towards oral insulin. Pharm. Res. 28, 886-896 (2011).
80. Gowthamarajan K, Kulkarni GT. Oral insulin -fact or fiction? Resonance 8(5), 38-46 (2003).
81. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17, 1159-1167 (2000).
82. Mao S, Bakowsky U, Jintapattankit A, Kissel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J. Pharm. Sci. 95, 1035-1048 (2006). (Pubitemid 43723163)
83. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld RJ. Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J. Nanosci. Nanotechnol. 7, 283-2841 (2007).
84. Shu S, Zhang X, Teng D, Wang Z, Li C. Polyelectrolyte nanoparticles based on water-soluble chitosan-poly(l-aspartic acid)-polyethylene glycol for controlled protein release. Carbohydr. Res. 344, 1197-1204 (2009).
85. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14(11), 1568-1573 (1997). (Pubitemid 28009208)
86. Bayat A, Dorkoosh FA, Dehpour AR et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int. J. Pharm. 356(1-2), 259-266 (2008).
87. Sarmento B, Ferreira D, Veiga F, Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr. Polym. 66, 1-7 (2006). (Pubitemid 44376662)
88. Sajeesh S, Sharma CP. Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery. J. Biomed. Mater. Res. B Appl. Biomater. 76B, 298-305 (2006). (Pubitemid 43165387)
89. Sun W, Mao S, Mei D, Kissel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin. Eur. J. Pharm. Biopharm. 69, 471-425 (2008).
90. Shu S, Wang X, Zhang X, Zhang X, Wang Z, Li C. Disulfide cross-linked biodegradable polyelectrolyte nanoparticles for the oral delivery of protein drugs. New J. Chem. 33, 1882-1887 (2009).
91. Mao S, Shuai X, Unger F, Wittmar M, Xie X, Kissel T. Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers. Biomaterials 26, 6343-6356 (2005). (Pubitemid 40828390)
92. Mao S, Germershaus O, Fischer D, Linn T, Schnepf R, Kissel T. Uptake and transport of PEG-grsft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm. Res. 22, 2058-2068 (2005). (Pubitemid 41821585)
93. Chen F, Zhang Z, Yuan F, Qin X, Wang M, Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm. 349, 226-233 (2008). (Pubitemid 350299699)
94. Bernkop-Schnürch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57, 1569-1582 (2005). (Pubitemid 41443470)
95. Albrecht K, Bernkop-Schnürch A. Thiomers: forms, functions and applications to nanomedicine. Nanomedicine 2(1), 41-50 (2007). (Pubitemid 46845775)
96. Föger F, Schmitz T, Bernkop-Schnürch A. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27(23), 4250-4255 (2006).
97. Sakloetsakun D, Iqbal J, Millotti G, Vetter A, Bernkop-Schnürch A. Thiolated chitosans: influence of various sulfhydryl ligands on permeation-enhancing and P-gp inhibitory properties. Drug Dev. Ind. Pharm. 37(6), 648-655 (2011).
98. Hu Y, Jiang X, Ding Y, Ge H, Yuan Y, Yang C. Synthesis and characterization of chitosan-poly(acrylic acid) nanoparticles. Biomaterials 23, 3193-3201 (2002). (Pubitemid 34525103)
99. El-Sherbiny IM. Synthesis, characterization and metal uptake capacity of a new carboxymethyl chitosan derivative. Eur. Polym. J. 45, 199-210 (2009).
100. El-Sherbiny IM. Enhanced pH-responsive carrier system based on alginate and chemically modified carboxymethyl chitosan for oral delivery of protein drugs: preparation and in vitro assessment. Carbohydr. Polym. 80, 1125-1136 (2010).
101. El-Sherbiny IM, Abdel-Bary EM, Harding DRK. Preparation and in vitro evaluation of new pH-sensitive hydrogel beads for oral delivery of protein drugs. J. Appl. Polym. Sci. 115(5), 2828-2837 (2010).
102. El-Sherbiny IM, Elmahdy MM. Preparation, characterization, structure and dynamics of carboxymethyl chitosan grafted with acrylic acid sodium salt. J. Appl. Polym. Sci. 118(4), 2134-2145 (2010).
103. Perera G, Greindl M, Palmberger T, Bernkop-Schnürch A. Insulin-loaded poly(acrylic acid)-cysteine nanoparticles: stability studies towards digestive enzymes in the intestine. Drug Deliv. 16, 254-260 (2009).
104. Thurow H, Geisen K. Stabilization of dissolved proteins against denaturation at hydrophobie interfaces. Diabetologia 27(2), 212-218 (1984). (Pubitemid 14067460)
105. Rahman NA, Mathiowitz E. Localization of bovine serum albumin in double-walled microspheres. J. Control. Release 94(1), 163-175 (2004). (Pubitemid 37542386)
106. Lowman AM, Cowans BA, Peppas NA. Investigation of interpolymer complexation in swollen polyelectolyte networks using solid-state NMR spectroscopy. J. Polym. Sci. B Polym. Phys. 38(21), 2823-2831 (2000).
107. Lankalapalli S, Kolapalli VRM. Polyelectrolyte complexes: a review of their applicability in drug delivery technology. Indian J. Pharm. Sci. 71(5), 481-487 (2009).
108. Woitiski CB, Neufeld RJ, Ribeiro AJ, Veiga F. Colloidal carrier integrating biomaterials for oral insulin delivery: influence of component formulation on physicochemical and biological parameters. Acta Biomater. 5, 2475-2484 (2009).
109. Jintapattanakit A, Junyaprasert VB, Mao S, Sitterberg J, Bakowsky U, Kissel T. Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int. J. Pharm. 342, 240-249 (2007). (Pubitemid 47259332)
110. Dupuy B, Arien A, Minnot AP. FT-IR of membranes made with alginate/polylysine complexes. Variations with the mannuronic or guluronic content of the polysaccharides. Artif. Cells Blood Substit. Immobil. Biotechnol. 22(1), 71-82 (1994). (Pubitemid 24204444)
111. Foss AC, Peppas NA. Investigation of the cytotoxicity and insulin transport of acrylic-based copolymer protein delivery systems in contact with Caco-2 cultures. Eur. J. Pharm. Biopharm. 57, 447-455 (2004). (Pubitemid 38490561)
112. López JE, Peppas NA. Effect of poly (ethylene glycol) molecular weight and microparticle size on oral insulin delivery from P(MAA-g-EG) microparticles. Drug Dev. Ind. Pharm. 30(5), 497-504 (2004). (Pubitemid 38821861)
113. Besheer A, Wood KM, Peppas NA, Mäder K. Loading and mobility of spin-labeled insulin in physiologically responsive complexation hydrogels intended for oral administration. J. Control. Release 111, 73-80 (2006). (Pubitemid 43289997)
114. Wood KM, Stone G, Peppas NA. The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomaterialia 6, 48-56 (2010).
115. American Diabetes Association. Standards of medical care in diabetes -2009. Current criteria for the diagnosis of diabetes. Diabetes Care 32(Suppl. 1), S6-S12 (2009).
116. Sugano K, Kansy M, Artursson P et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597-614 (2010).
117. Bae KH, Moon CW, Lee Y, Park TG. Intracellular delivery of heparin complexed with chitosan-g-poly(ethylene glycol) for inducing apoptosis. Pharm. Res. 26(1), 93-100 (2009).